EP1982982A4 — NEW COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY
Assigned to Chugai Pharmaceutical Co Ltd · Expires 2009-07-22 · 17y expired
What this patent protects
It is intended to provide a compound represented by the following general formula (1) or a pharmaceutically acceptable salt thereof. Because of having a sufficiently high antitumor activity, this compound or its salt is useful as a remedy for cell proliferative diseases, in parti…
USPTO Abstract
It is intended to provide a compound represented by the following general formula (1) or a pharmaceutically acceptable salt thereof. Because of having a sufficiently high antitumor activity, this compound or its salt is useful as a remedy for cell proliferative diseases, in particular, cancer. It is also intended to provide a medicinal composition which contains the above-described compound or its salt as the active ingredient. [Chemical formula 1] (1) wherein X is selected from heteroaryl, etc.; Y1 and Y2 are selected from -N=, etc.; Y3 and Y4 are selected from -CH=, etc.; A is selected from sulfamide, etc.; R1 is selected from hydrogen, etc.; and R2 is selected from C1-6 alkyl, etc.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.